Evidence map›Paper›PMID 32650834›Full record

ArticleJournal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale2020

Clinicopathologic implications of Myb and Beta-catenin expression in adenoid cystic carcinoma.

Susan Park, Manali Vora, Annemieke van Zante, Joseph Humtsoe, Hyun-Su Kim, Sue Yom, Shweta Agarwal, Patrick Ha

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Susan ParkColumbia University College of Dental Medicine, New York, NY, USA.
Manali VoraDepartment of Otolaryngology Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA.
Annemieke van ZanteDepartment of Pathology, University of California San Francisco, San Francisco, California, USA.
Joseph HumtsoeDepartment of Otolaryngology Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA.
Hyun-Su KimDepartment of Otolaryngology Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA.
Sue YomDepartment of Radiation Oncology, University of California San Francisco, San Francisco, California, USA.
Shweta AgarwalDepartment of Pathology, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Patrick HaDepartment of Otolaryngology Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA. patrick.ha@ucsf.edu.ORCID http://orcid.org/0000-0003-0306-6147
University of California, San Francisco · USUniversity of New Mexico · US

Funding

Integrated pathway analysis of altered driver genes in adenoid cystic carcinomaR01DE023227 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HA, PATRICK KYONGMIN · 2012 to 2015
$1.6M
NIDCR NIH HHS R01 DE023227NIH HHS R01DE023227
6 · The paper itself

Abstract

backgroundAdenoid cystic carcinoma (ACC) is the second most common malignancy of the salivary glands, accounting for ~ 1% of malignant tumors of the head and neck region and 10% of salivary gland neoplasms. Predicting the long-term outcomes of patients with ACC is still challenging, as reliable prognostic biomarkers are not available. Among salivary gland tumors, Myb overexpression is highly specific for ACC. In addition, the MYB-NF1B fusion translocation is a hallmark of ACC, and although the detection of this translocation does not appear to impact prognosis, the MYB-NF1B fusion is also implicated in MYB upregulation. Myb has recently been identified as an activator of the Wnt/β-catenin signaling pathway, and aberrant cytoplasmic expression of β-catenin has been observed in many salivary gland malignancies. In this study, we aim to analyze the impact of Myb and β-catenin expression on prognosis in ACC.

methodsA tissue microarray constructed from archival tissue from 64 patients with ACC was stained for Myb and β-catenin; both localization and intensity were evaluated. In parallel, we abstracted demographic data, tumor characteristics, survival data, and outcomes, including local recurrence, regional recurrence, and distant metastasis from the medical record. Statistical analysis was performed.

resultsOur analysis supports that ACC patients negative for Myb by immunohistochemical methods have a higher risk of developing metastasis than patients with Myb staining (HR: 4.06, 95% CI: 1.02-14.96, p-value: 0.03). Although not statistically significant, cytoplasmic localization of β-catenin is may suggest a diminished rate of relapse-free survival (HR 2.45, 95%CI: 0.9-6.7, p = 0.08). Furthermore, Myb expression correlated with β-catenin expression, increasing 1.69 in staining intensity units with each increase in β-catenin staining intensity (p-value: 0.04).

conclusionsOur study suggests that Myb expression is protective; Myb positive patients have diminished risk of distant metastasis. In contrast, there is a trend towards increased hazard of death in ACC patients with cytoplasmic β-catenin expression. Additional analyses will be necessary to establish Myb and β-catenin as independent protective and adverse biomarkers, respectively.

Indexed as

Age of Onsetbeta CateninBiomarkers, TumorCarcinoma, Adenoid CysticFemaleHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalPrognosisProto-Oncogene Proteins c-mybSalivary Gland NeoplasmsTissue Array AnalysisTranslocation, Geneticbeta CateninBiomarkers, TumorCTNNB1 protein, humanMYB protein, humanProto-Oncogene Proteins c-mybAdenoid cystic carcinomaBeta-cateninMybPrognostic indicator

Identifiers

PMID32650834
PMCPMC7350736
OpenAlexW3041540934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.